Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStomach pain is one of the most commonly reported side effects of Mounjaro (tirzepatide). It tends to appear after starting treatment or after a dose increase, usually settles within a few days to two weeks, and is linked to how tirzepatide slows digestion. That said, not all stomach pain during Mounjaro treatment is routine — some patterns need prompt medical attention. This page explains the difference, drawing on NHS guidance on tirzepatide and MHRA safety communications. Mounjaro is a prescription-only medicine; a prescriber assesses whether it is clinically suitable for you before it is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide works by activating two gut-hormone receptors (GIP and GLP-1) which together slow the rate at which the stomach empties. Food sits in the stomach longer, and that slower transit time is part of why appetite falls. It is also, frankly, why many people feel discomfort. When digestion slows, gas builds, the gut wall stretches, and the result can be cramping, bloating, or a dull ache in the upper abdomen.
The timing is fairly predictable. Symptoms are most likely in the 24 to 48 hours after an injection, and they tend to be sharpest in the first weeks at any given dose. For most people they ease considerably once the body adjusts. The full side-effect picture with Mounjaro goes beyond the stomach, but GI effects are reliably the most common category across the clinical trial programme.
If your pain sits alongside nausea, loose stools or excessive burping, that is a well-documented pattern. There is more detail on the digestive cluster specifically at Mounjaro, stomach pain and diarrhoea.
Mild-to-moderate cramping or aching that comes on within a day or two of your injection, improves on its own within a week, and does not stop you going about your day is typical for the early weeks of treatment. It usually sits in the upper-middle abdomen, sometimes alongside nausea or a feeling of fullness that arrives quickly at meals.
Several practical adjustments help. Smaller portions at each meal reduce the gastric load. High-fat or very rich food reliably worsens GI symptoms on tirzepatide. Eating slowly and avoiding lying down immediately after a meal also makes a difference. Keeping fluid intake up matters too — persistent nausea can quietly lead to dehydration if you are not drinking enough.
If discomfort is concentrated lower in the gut, with cramping and loose stools, the combination is common enough that it is worth reading about stomach cramps and diarrhoea on Mounjaro separately. Sulphur burping alongside pain is another documented pattern, covered at sulphur burps and stomach pain on Mounjaro.
This is the part that matters most. On 29 January 2026 the MHRA issued a Drug Safety Update for GLP-1 receptor agonist medicines, identifying acute pancreatitis as a known (though infrequent) serious risk. The warning sign is severe stomach pain that does not ease, often radiating through to the back, and which may or may not be accompanied by vomiting. If that description fits what you are experiencing, stop waiting for it to pass and seek urgent medical care.
Other patterns that warrant prompt attention: pain that is getting progressively worse rather than settling, pain severe enough to affect your breathing or posture, or any combination of intense abdominal pain with fever, jaundice (yellowing of the skin or eyes), or very dark urine, which can indicate a gallbladder problem. Gallstone-related issues are a recognised risk with GLP-1 medicines, given the rate of weight loss.
The NHS patient page for tirzepatide on nhs.uk lists the symptoms that need urgent review. If you are unsure whether your pain falls into the concerning category, contact your prescriber, call 111, or go to your nearest urgent treatment centre. Do not try to manage ambiguous or escalating pain at home by reducing your dose.
Back pain sometimes appears alongside abdominal discomfort on tirzepatide, if that applies to you, is back pain a side effect of Mounjaro covers the evidence on that question directly.
If you know a dose increase is coming, the most useful thing is to plan your meals around it. The 48 hours post-injection are the window where symptoms peak, so keeping food lighter and lower in fat during that period reduces the trigger load. Alcohol amplifies gastric irritation and is worth cutting back during the adjustment weeks.
Staying hydrated is not a cliché here, it is genuinely protective. Persistent nausea makes people drink less, which concentrates digestive acids and makes pain worse. Small, regular sips of water throughout the day work better than large glasses when your stomach is unsettled.
If symptoms are significant and not settling, your prescriber can review your pace of dose escalation. Titration is not a race, spending longer at a lower dose before stepping up is a legitimate clinical choice, not a failure. That conversation starts with the people looking after your treatment.
If you are considering starting treatment, our prescribers discuss side effects including stomach pain as part of every consultation. You can start your free consultation and get a same-day clinical review from a GPhC-registered prescriber. For a broader view of what Mounjaro treatment involves, the Mounjaro overview is a good starting point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.